Sai Parenterals Ltd
- Market cap
- ₹ 2,004 Cr.
- P/E
- 150x
- P/B
- 4.06x
- 52-week range
- 400 – 706
- ROE
- 5%
- ROCE
- 6%
- Dividend yield
- 0%
- Debt / equity
- 0.96
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. It is in the business of branded generic formulations and contract development and manufacturing organizational products and services for the domestic and international markets. Its portfolio includes formulation products across various therapeutic areas like cardiovascular, neruopsychiatry, anti-diabetic, respiratory health, antibiotics, vitamins, minerals and supplements analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, the Company has capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampules, and vials. It manufactures and sells branded generic formulations to a diverse customer base, including central and state government agencies.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Sai Parenterals Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)150 against a typical 34.6: pricier than most peers (1st = cheapest).204th of 220
- Share price, 3 months−13.1% against a typical −0.5%.159th of 200
- Size₹ 2,003.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).70th of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 1 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 11 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 23 May 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 20 Apr 2026 | Other business matters | To consider other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 33 | 96 | 198 | 179 |
| Expenses | 29 | 100 | 172 | 155 |
| Operating Profit | 5 | −4 | 26 | 24 |
| OPM % | 14.2% | −3.7% | 13.2% | 13.2% |
| Other Income | 1 | 3 | 3 | 4 |
| Interest | 2 | 5 | 8 | 9 |
| Depreciation | 1 | 6 | 8 | 8 |
| Profit before tax | 2 | −12 | 12 | 10 |
| Tax % | 29.5% | −42.7% | −6.1% | 19% |
| Net Profit | 1 | −7 | 13 | 8 |
| EPS in Rs | 0.52 | −1.8 | 2.98 | 1.79 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 58%
- TTM
- 134%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 48%
- TTM
- −1%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 9%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Sai Parenterals Ltd | ₹ 480.20 | ₹ 2,004 Cr. | 150x | 4.1x | 5% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Anil Kumar Karusala
- Executive Chairman, Managing Director
- D.B.Venkoji Prakash
- Chief Executive Officer
- Anil Kumar
- Chief Financial Officer
- Shivali Aggarwal
- Company Secretary, Compliance Officer
- Vijitha Gorrepati
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.